Specifically, genetic suppression of GTK inhibited tumor formation in vivo and thus this enzyme provides a promising target for the development of selective GTK inhibitors to combine with existing GLS1 inhibitors for the treatment of pancreatic cancer. The gene discussed is KYAT1; the disease is pancreatic neoplasm.